Oragenics Inc Cash Flow Conversion Efficiency
Oragenics Inc cash flow conversion efficiency. Based on the latest financial reports, Oragenics Inc (OGEN) has a cash flow conversion efficiency ratio of -0.356x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.20 Million) by net assets ($6.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oragenics Inc (2003–2025)
Cash flow conversion efficiency of Oragenics Inc from 2003 to 2025. This chart illustrates how Oragenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OGEN stock price and chart for real-time trading data and today's change.
Oragenics Inc Cash Flow Conversion Ratio Explained
Oragenics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oragenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oragenics Inc ranked by their cash flow conversion efficiency. Also see Oragenics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rocky Mountain Liquor Inc
V:RUM
|
0.030x |
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
-0.581x |
|
Aptevo Therapeutics Inc
NASDAQ:APVO
|
-0.903x |
|
GENERIC GOLD CORP.
F:1WD
|
N/A |
|
Iveda Solutions Inc
NASDAQ:IVDA
|
-0.053x |
|
WORK Medical Technology Group LTD Ordinary Shares
NASDAQ:WOK
|
0.427x |
|
Performance One AG
F:PO1
|
N/A |
|
Roadman Investments Corp
V:LITT
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Oragenics Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Oragenics Inc from 2003 to 2025. Review Oragenics Inc (OGEN) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.28 Million | $-9.25 Billion | -1116.524x | -2851.71% |
| 2024-12-31 | $-211.88K | $-8.60 Million | 40.576x | +1863.16% |
| 2023-12-31 | $3.17 Million | $-7.29 Million | -2.301x | -96.59% |
| 2022-12-31 | $13.01 Million | $-15.23 Million | -1.171x | -130.17% |
| 2021-12-31 | $26.49 Million | $-13.47 Million | -0.509x | +49.47% |
| 2020-12-31 | $16.84 Million | $-16.95 Million | -1.006x | -33.27% |
| 2019-12-31 | $17.23 Million | $-13.01 Million | -0.755x | -73.68% |
| 2018-12-31 | $20.88 Million | $-9.08 Million | -0.435x | +56.84% |
| 2017-12-31 | $6.32 Million | $-6.36 Million | -1.008x | +57.77% |
| 2016-12-31 | $2.97 Million | $-7.08 Million | -2.386x | -121.11% |
| 2015-12-31 | $4.73 Million | $-5.10 Million | -1.079x | -100.60% |
| 2014-12-31 | $10.34 Million | $-5.56 Million | -0.538x | -25.93% |
| 2013-12-31 | $15.84 Million | $-6.76 Million | -0.427x | +24.35% |
| 2012-12-31 | $9.23 Million | $-5.21 Million | -0.565x | -184.04% |
| 2011-12-31 | $-8.18 Million | $-5.49 Million | 0.672x | -80.21% |
| 2010-12-31 | $-1.90 Million | $-6.45 Million | 3.395x | +254.53% |
| 2009-12-31 | $2.64 Million | $-5.80 Million | -2.197x | -110.15% |
| 2008-12-31 | $-177.25K | $-3.84 Million | 21.637x | +1026.98% |
| 2007-12-31 | $819.88K | $-1.91 Million | -2.334x | -34.13% |
| 2006-12-31 | $1.28 Million | $-2.22 Million | -1.740x | +10.23% |
| 2005-12-31 | $1.77 Million | $-3.43 Million | -1.939x | -185.04% |
| 2004-12-31 | $4.04 Million | $-2.75 Million | -0.680x | -91.94% |
| 2003-12-31 | $3.44 Million | $-1.22 Million | -0.354x | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more